NL-201

NL-201 was an immunotherapy drug candidate that underwent a Phase 1 human clinical trial in cancer patients. It is a de novo protein that was first computationally designed at the Institute of Protein Design (IPD), University of Washington. In November 2022, Neoleukin Therapeutics announced it would discontinue the development of NL-201.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.